Addex Therapeutics Ltd (ADXN.SW)

0.0650 -0.0010 (-1.52%) At close: 05:30PM CEST

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
Switzerland
41 22 884 1555
https://www.addextherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 23

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Timothy Mark Dyer	Co-Founder, CEO & Director	N/A	N/A	1968
Dr. Roger G. Mills M.D.	Chief Medical Officer & Director	N/A	N/A	1957
Mr. Lénaic Teyssédou	Head of Finance	N/A	N/A	1986
Dr. Mikhail Kalinichev Ph.D.	Head of Translational Science	N/A	N/A	1967

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Corporate governance

Addex Therapeutics Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.